^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
DDCAR-CD19 T-cells
i
Other names: DDCAR-CD19 T-cells
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Aghia Sophia Children’s Hospital
Drug class:
CD19-targeted CAR-T immunotherapy
Related drugs:
2years
A Phase 2 Study of the Efficacy and Safety of a Dose of Donor-Derived CD19-targeted CAR T cells Κλινική Μελέτη φάσης 2 για την αποτελεσματικότητα και την ασφάλεια χορήγησης αλλογενών Τ λεμφοκυττάρων με χιμαιρικό υποδοχέα αντι-CD19 (CAR-T) (clinicaltrialsregister.eu)
P2, N=8, Ongoing, Aghia Sophia Children’s Hospital
New P2 trial • CAR T-Cell Therapy
|
CD19 (CD19 Molecule)
|
DDCAR-CD19 T-cells
Share via
